INSIDE INDUSTRY

2017 ◽  
Vol 21 (11) ◽  
pp. 32-43
Keyword(s):  
Drug Delivery ◽  
Clinical Trial ◽  
Fragility Fractures ◽  
Asia Pacific ◽  
European Patent ◽  
Medical Cannabis ◽  
The Us ◽  
Long Acting ◽  
Drug Delivery Devices ◽  
Delivery Technology

APAC drug delivery devices market to reach $5.4 billion in 2023. Mergermarket released Global Pharma, Medical & Biotech trend report for Q3 2017. Global BioLife develops breakthrough modified sugar. Breakthrough noodle formula with low-glycemic score of 38. Aphria ships first medical cannabis oil to Australia’s Medlab for clinical trial. Envirotainer doubles e-technology capacity across Asia. Genesis CancerCare Queensland is first in Asia-Pacific to use Elekta’s Venezia Brachytherapy Applicator. iX Biopharma secures European patent for WaferiX drug delivery technology. Shingrix approved in the US for prevention of shingles in adults aged 50 and over. First three-monthly long-acting treatment for schizophrenia patients in Singapore. China, Brazil and Russia named by healthcare companies as riskiest markets for compliance and regulation. New survey shows patients in Asia Pacific fail to recognize their fragility fracture is due to osteoporosis. Healthcare community join forces to fight growing epidemic of fragility fractures caused by osteoporosis.

scholarly journals Industry update May 2019

2019 ◽  
Vol 10 (10) ◽  
pp. 613-620
Author(s):  
Elaine Harris
Keyword(s):  
Drug Delivery ◽  
Clinical Trial ◽  
Balloon Catheter ◽  
Sources Of Information ◽  
Press Releases ◽  
News Websites ◽  
The Us ◽  
Us Fda ◽  
Clinical Trial Results ◽  
Drug Coated Balloon

The present industry update covers the period 1–31 May 2019. Sources of information included company press releases, regulatory and patent agencies notices, and various news websites. This month saw the announcement that world-renowned MIT scientist, Robert Langer is to be awarded the 2019 Dreyfus Prize for Chemistry for his contribution to drug delivery. Several notable collaborations were announced this month including Intec to partner with Merck on development of products using Intec's ‘Accordion Pill’ and Zylö Therapeutics to use its Nanopods™ in a partnership with Hoth Therapeutics to develop a treatment for lupus. Approvals this month include concept receiving ‘Breakthrough Device designation’ from the US FDA for its CE-marked sirolimus drug-coated balloon catheter, MagicTouch. Tocsagen and Insmed released positive late stage clinical trial results for products employing advanced delivery technologies.

Recent In Vitro and In Silico Advances in the Understanding of Intranasal Drug Delivery

2020 ◽  
Vol 26 ◽  
Author(s):  
John Chen ◽  
Andrew Martin ◽  
Warren H. Finlay
Keyword(s):  
Drug Delivery ◽  
In Silico ◽  
Local Drug Delivery ◽  
In Vivo Studies ◽  
Intranasal Drug Delivery ◽  
Nasal Sprays ◽  
In Silico Studies ◽  
Drug Delivery Devices

Background: Many drugs are delivered intranasally for local or systemic effect, typically in the form of droplets or aerosols. Because of the high cost of in vivo studies, drug developers and researchers often turn to in vitro or in silico testing when first evaluating the behavior and properties of intranasal drug delivery devices and formulations. Recent advances in manufacturing and computer technologies have allowed for increasingly realistic and sophisticated in vitro and in silico reconstructions of the human nasal airways. Objective: To perform a summary of advances in understanding of intranasal drug delivery based on recent in vitro and in silico studies. Conclusion: The turbinates are a common target for local drug delivery applications, and while nasal sprays are able to reach this region, there is currently no broad consensus across the in vitro and in silico literature concerning optimal parameters for device design, formulation properties and patient technique which would maximize turbinate deposition. Nebulizers are able to more easily target the turbinates, but come with the disadvantage of significant lung deposition. Targeting of the olfactory region of the nasal cavity has been explored for potential treatment of central nervous system conditions. Conventional intranasal devices, such as nasal sprays and nebulizers, deliver very little dose to the olfactory region. Recent progress in our understanding of intranasal delivery will be useful in the development of the next generation of intranasal drug delivery devices.

Recent Advances in Gastric Floating Drug Delivery Technology: A Review

2013 ◽  
Vol 10 (3) ◽  
pp. 286-298 ◽  
Author(s):  
Rakesh Pahwa ◽  
Seema Bisht ◽  
Vipin Kumar ◽  
Kanchan Kohli
Keyword(s):  
Drug Delivery ◽  
Recent Advances ◽  
Floating Drug Delivery ◽  
Delivery Technology

Anti-VEGFR2 Antibody-modified Micelle for Triggered Drug Delivery and Effective Therapy of Choroidal Neovascularization

2019 ◽  
Vol 16 (3) ◽  
pp. 258-265
Author(s):  
Kei Takahashi ◽  
Tomomi Masuda ◽  
Mitsunori Harada ◽  
Tadashi Inoue ◽  
Shinsuke Nakamura ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Choroidal Neovascularization ◽  
Pigment Epithelium ◽  
Drug Carrier ◽  
Retinal Pigment ◽  
Laser Coagulation ◽  
Antiangiogenic Agents ◽  
Drug Carrier System ◽  
Novel Drug ◽  
Drug Delivery Devices

Objective: This study aimed to examine whether DC101 (anti-VEGFR2 antibody)- modified micelles have applications as novel drug delivery devices, which allow small molecule antiangiogenic agents to deliver to angiogenic sites on a murine laser-induced choroidal neovascularization (CNV) model. Materials and Method: CNV was induced by photocoagulation on the unilateral eye of each mouse under anesthesia. Immediately after laser coagulation, E7974-loaded DC101-modified micelles and motesanib-loaded DC101-modified micelles were intravitreally administrated. Two weeks after photocoagulation, CNV was visualized using fluorescein-conjugated dextran (MW=2,000 kDa), and the CNV area was measured in retinal pigment epithelium (RPE)-choroidal flat mounts. Results: Intravitreal administration of both DC101-modified micelles loaded with E7974 at 2 µM and motesanib at 2 µM significantly reduced CNV area in the murine laser-induced CNV model at a clearly lower concentration than the effective dose of each agent. Conclusion: These results suggest that DC101-modified micelle might be effective drug carrier system for treating CNV and other ocular angiogenic diseases.

scholarly journals Tuberculosis and viral hepatitis in patients treated with certolizumab pegol in Asia-Pacific countries and worldwide: real-world and clinical trial data

2020 ◽  
Author(s):  
Chak Sing Lau ◽  
Yi-Hsing Chen ◽  
Keith Lim ◽  
Marc de Longueville ◽  
Catherine Arendt ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Viral Hepatitis ◽  
Central Europe ◽  
Real World ◽  
Certolizumab Pegol ◽  
Safety Data ◽  
Asia Pacific ◽  
Hbv Reactivation ◽  
Post Marketing

Abstract Introduction/objectives To evaluate the incidence rate (IR) of tuberculosis (TB) and viral hepatitis B and C (HBV/HCV) during certolizumab pegol (CZP) treatment, worldwide and in Asia-Pacific countries, across clinical trials and post-marketing reports (non-interventional studies and real-world practice). Method CZP safety data were pooled across 49 clinical trials from 1998 to June 2017. Post-marketing reports were from initial commercialization until March 2015 (TB)/February 2017 (HBV/HCV). All suspected TB and HBV/HCV cases underwent centralized retrospective review by external experts. Incidence rates (IRs) were calculated per 100 patient-years (PY) of CZP exposure. Results Among 11,317 clinical trial patients (21,695 PY), 62 TB cases were confirmed (IR 0.29/100 PY) including 2 in Japan (0.10/100 PY) and 3 in other Asia-Pacific countries (0.58/100 PY). From > 238,000 PY estimated post-marketing CZP exposure, there were 31 confirmed TB cases (0.01/100 PY): 5 in Japan (0.05/100 PY), 1 in other Asia-Pacific countries (0.03/100 PY). Reported regional TB IRs were highest in eastern Europe (0.17/100 PY), central Europe (0.09/100 PY), and Mexico (0.16/100 PY). Across clinical trials, there was 1 confirmed HBV reactivation and no HCV cases. From > 420,000 PY estimated post-marketing CZP exposure, 5 HBV/HCV cases were confirmed (0.001/100 PY): 2 HCV reactivations; 1 new HCV; plus 2 HBV reactivations in Japan (0.008/100 PY). Conclusions CZP TB risk is aligned with nationwide TB rates, being slightly higher in Asia-Pacific countries excluding Japan. Overall, TB and HBV/HCV risk with CZP treatment is currently relatively low, as risk can be minimized with patient/physician education, screening, and vigilant treatment, according to international guidelines. Key Points:• TB rates were highest in eastern/central Europe, Mexico, and Asia-Pacific regions.• With the implementation of stricter TB screening and risk evaluations in 2007, especially in high TB incidence countries, there was a notable reduction TB occurrence.• Safety profile of biologics in real-world settings complements controlled studies.• TB and hepatitis (HBV/HCV) risk with certolizumab pegol (CZP) treatment is low.

Sign in / Sign up

Export Citation Format

Share Document